Your browser doesn't support javascript.
loading
EZH2 Loss Drives Resistance to Carboplatin and Paclitaxel in Serous Ovarian Cancers Expressing ATM.
Naskou, Johanna; Beiter, Yvonne; van Rensburg, Ruan; Honisch, Ellen; Rudelius, Martina; Schlensog, Martin; Gottstein, Julia; Walter, Larissa; Braicu, Elena I; Sehouli, Jalid; Darb-Esfahani, Silvia; Staebler, Annette; Hartkopf, Andreas D; Brucker, Sara; Wallwiener, Diethelm; Beyer, Ines; Niederacher, Dieter; Fehm, Tanja; Templin, Markus F; Neubauer, Hans.
Afiliação
  • Naskou J; Department of Obstetrics and Gynecology, Heinrich Heine University Düsseldorf, Düsseldorf, Germany.
  • Beiter Y; Pharmaceutical Biotechnology, Eberhard Karls University of Tübingen, Tübingen, Germany.
  • van Rensburg R; Pharmaceutical Biotechnology, Eberhard Karls University of Tübingen, Tübingen, Germany.
  • Honisch E; NMI Technologietransfer GmbH, Reutlingen, Germany.
  • Rudelius M; Department of Obstetrics and Gynecology, Heinrich Heine University Düsseldorf, Düsseldorf, Germany.
  • Schlensog M; Department of Obstetrics and Gynecology, Heinrich Heine University Düsseldorf, Düsseldorf, Germany.
  • Gottstein J; Department of Pathology, Ludwig Maximilian University of Munich, Munich, Germany.
  • Walter L; Department of Pathology, Heinrich Heine University Düsseldorf, Düsseldorf, Germany.
  • Braicu EI; Department of Obstetrics and Gynecology, Heinrich Heine University Düsseldorf, Düsseldorf, Germany.
  • Sehouli J; Natural and Medical Sciences Institute at the University of Tübingen, Reutlingen, Germany.
  • Darb-Esfahani S; Department of Gynecology, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin and Berlin Institute of Health, Germany.
  • Staebler A; Tumor Bank Ovarian Cancer Network (TOC), Berlin, Germany.
  • Hartkopf AD; Department of Gynecology, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin and Berlin Institute of Health, Germany.
  • Brucker S; Tumor Bank Ovarian Cancer Network (TOC), Berlin, Germany.
  • Wallwiener D; Department of Pathology, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin and Berlin Institute of Health, Germany.
  • Beyer I; Tumor Bank Ovarian Cancer Network (TOC), Berlin, Germany.
  • Niederacher D; Department of Pathology and Neuropathology, Eberhard Karls University of Tübingen, Tübingen, Germany.
  • Fehm T; Department of Obstetrics and Gynecology, University Hospital of Tübingen, Tübingen, Germany.
  • Templin MF; Department of Obstetrics and Gynecology, University Hospital of Tübingen, Tübingen, Germany.
  • Neubauer H; Department of Obstetrics and Gynecology, University Hospital of Tübingen, Tübingen, Germany.
Mol Cancer Res ; 18(2): 278-286, 2020 02.
Article em En | MEDLINE | ID: mdl-31704732
Assuntos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neoplasias Ovarianas / Carboplatina / Paclitaxel / Cistadenocarcinoma Seroso / Proteínas Mutadas de Ataxia Telangiectasia / Proteína Potenciadora do Homólogo 2 de Zeste Idioma: En Ano de publicação: 2020 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neoplasias Ovarianas / Carboplatina / Paclitaxel / Cistadenocarcinoma Seroso / Proteínas Mutadas de Ataxia Telangiectasia / Proteína Potenciadora do Homólogo 2 de Zeste Idioma: En Ano de publicação: 2020 Tipo de documento: Article